

SK bioscience appoints new executives towards global business growth

22 October 2022 | News

Global experts continue to join SK bioscience, while its US corporate entity is being established

South Korea-based SK bioscience has announced that Dr Harry Kleanthous, formerly Senior Programme Officer in Global Health at the Bill & Melinda Gates Foundation (BMGF), has joined the company as Executive Vice President of vaccine R&D strategy and external innovation.

Dr Kleanthous, an expert in the vaccine field, has devoted 30 years to the vaccine industry in both biotech & large biopharma, serving as Vice President Research at Acambis, and Head of Research for North America at Sanofi Pasteur, where he developed innovative platforms and developed pipelines targeting medically important infectious diseases.

In support of expanding its globalisation efforts, SK bioscience has named Dr Sally Choe, an expert in drug review, clinical pharmacology, and medical product development, as Head of Global Clinical Development and Regulatory Affairs of the Company. In this role, she will be leading the company's clinical development and execution of innovative products and regulatory affairs to advance SK bioscience's global competitiveness.

Dr Sally joins SK bioscience from the US Food and Drug Administration (FDA) where she most recently served as the Super Office Director of the Office of Generic Drugs (OGD). Prior to her 12 years of tenure at the FDA, she worked at Parexel Regulatory Consulting firm as Senior Director, and also worked in large biopharma including Bristol Myers Squibb (BMS) and Pfizer.